Laviv
LAVIV™ is the first and only FDA-approved autologous cellular therapy to improve the appearance of moderate to severe nasolabial fold wrinkles.LAVIV™ is an autologous cellular product containing fibroblast cells, which are grown from a patient’s post-auricular skin biopsy tissue. These skin samples are sent to a lab where they are aseptically expanded until sufficient cells for treatment are obtained. Cells are then cryopreserved. Over a period of approximately 90 days, hundreds of millions of fibroblasts are cultured at the lab and then frozen, until needed for treatment. Once patient administration has been scheduled, these cells are thawed, washed, and ready to be injected. LAVIV™—which is made up of at least 98% pure fibroblasts—places a patient’s own living cells into the treatment area to biologically improve the appearance of nasolabial fold wrinkles.
What makes LAVIV™ unique?
Each patient’s LAVIV™ treatment is unique because it is made from that patient’s own skin cells. In order to be approved by the FDA, LAVIV™ was held to high efficacy standards. In clinical trials, LAVIV™ demonstrated a statistically significant improvement as measured by both a physician and patient assessment scale, where improvement was defined as a 2-point improvement on the scales. These trials were designed to be vehicle-controlled and demonstrate superiority to vehicle. Each dose of LAVIV™ is also held to strict testing standards to ensure product performance and safety.
LAVIV™ is an appropriate treatment for adults who desire an improved appearance of nasolabial fold wrinkles, an autologous cellular product, and a treatment regimen that delivers gradual results.
